While evidence for angiogenic activity of AR in breast cancer is sparse, regulation of angiogenesis by AR in prostate cancer is implicated through interactions with epigenetic and transcriptional co-activation factors to regulate VEGF, and synergy between anti-androgenic and anti-VEGF therapies [34]. The gene discussed is VEGFA; the disease is prostate cancer.